JP2014516074A5 - - Google Patents

Download PDF

Info

Publication number
JP2014516074A5
JP2014516074A5 JP2014514172A JP2014514172A JP2014516074A5 JP 2014516074 A5 JP2014516074 A5 JP 2014516074A5 JP 2014514172 A JP2014514172 A JP 2014514172A JP 2014514172 A JP2014514172 A JP 2014514172A JP 2014516074 A5 JP2014516074 A5 JP 2014516074A5
Authority
JP
Japan
Prior art keywords
alkyl
methyl
cycloalkyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2014514172A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014516074A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2012/052627 external-priority patent/WO2012168817A1/en
Publication of JP2014516074A publication Critical patent/JP2014516074A/ja
Publication of JP2014516074A5 publication Critical patent/JP2014516074A5/ja
Ceased legal-status Critical Current

Links

JP2014514172A 2011-06-07 2012-05-24 ピラゾロ[3,4−d]ピリミジン化合物ならびにそのPDE2阻害剤および/またはCYP3A4阻害剤としての使用 Ceased JP2014516074A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161494070P 2011-06-07 2011-06-07
US61/494,070 2011-06-07
PCT/IB2012/052627 WO2012168817A1 (en) 2011-06-07 2012-05-24 Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors

Publications (2)

Publication Number Publication Date
JP2014516074A JP2014516074A (ja) 2014-07-07
JP2014516074A5 true JP2014516074A5 (enExample) 2015-07-09

Family

ID=46298646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014514172A Ceased JP2014516074A (ja) 2011-06-07 2012-05-24 ピラゾロ[3,4−d]ピリミジン化合物ならびにそのPDE2阻害剤および/またはCYP3A4阻害剤としての使用

Country Status (11)

Country Link
US (1) US8829010B2 (enExample)
EP (1) EP2718295A1 (enExample)
JP (1) JP2014516074A (enExample)
KR (1) KR101626681B1 (enExample)
CN (1) CN103596956A (enExample)
AU (1) AU2012265970A1 (enExample)
CA (1) CA2836851C (enExample)
IL (1) IL229606A0 (enExample)
MX (1) MX2013014470A (enExample)
SG (1) SG195085A1 (enExample)
WO (1) WO2012168817A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
JP6000273B2 (ja) 2010-11-29 2016-09-28 オーエスアイ・ファーマシューティカルズ,エルエルシー 大環状キナーゼ阻害剤
WO2014126954A1 (en) * 2013-02-13 2014-08-21 OSI Pharmaceuticals, LLC Regioselective synthesis of substituted pyrimidines
CN104098574A (zh) * 2013-04-12 2014-10-15 苏州科捷生物医药有限公司 氮杂环丁烷取代嘧啶类化合物及其用途
US9961897B2 (en) * 2013-08-20 2018-05-08 E I Du Pont De Nemours And Company Fungicidal pyrazoles
WO2015096651A1 (en) 2013-12-23 2015-07-02 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as pde2 inhibitors
EP3091983B1 (en) 2014-01-08 2019-10-02 Intra-Cellular Therapies, Inc. Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor
EP3134413B1 (en) 2014-04-23 2019-09-11 Dart NeuroScience (Cayman) Ltd. Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as pde2 inhibitors
JP2017114764A (ja) * 2014-04-25 2017-06-29 武田薬品工業株式会社 片頭痛治療剤
WO2016073424A1 (en) 2014-11-05 2016-05-12 Dart Neuroscience, Llc Substituted 5-methyl-[1, 2, 4] triazolo [1,5-a) pyrimidin-2-amine compounds as pde2 inhibitors
AU2015357498B2 (en) 2014-12-06 2019-09-12 Intra-Cellular Therapies, Inc. Organic compounds
US10300064B2 (en) * 2014-12-06 2019-05-28 Intra-Cellular Therapies, Inc. Organic compounds
EP3237401B1 (en) 2014-12-22 2019-03-06 Pfizer Inc Antagonists of prostaglandin ep3 receptor
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
WO2016154081A1 (en) 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as pde2 inhibitors
US10195201B2 (en) 2015-05-05 2019-02-05 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as PDE2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
US10647727B2 (en) 2015-06-25 2020-05-12 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
ES2962865T3 (es) 2016-11-18 2024-03-21 Integrative Res Laboratories Sweden Ab Nuevos derivados de azetidina útiles como moduladores de la neurotransmisión catecolaminérgica cortical
PT3713572T (pt) 2017-11-23 2025-08-28 Oslo Univ Hospital Hf Tratamento da taquicardia
EP4056571A4 (en) * 2019-11-09 2024-01-24 Shanghai Simr Biotechnology Co., Ltd. Tricyclic dihydroimidazopyrimidone derivative, preparation method therefor, pharmaceutical composition and use thereof
CN113244395B (zh) * 2020-02-10 2024-07-23 广州市妇女儿童医疗中心 纤维化疾病机制及其治疗药物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117909A2 (en) * 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
MX2007008137A (es) 2005-01-05 2007-07-19 Altana Pharma Ag Triazoloftalazinas como inhibidores de pde2.
EA012211B1 (ru) 2005-01-07 2009-08-28 Пфайзер Продактс Инк. Гетероароматические соединения хинолинов и их применение в качестве ингибиторов pde10
CN102020645B (zh) * 2010-09-30 2012-12-12 中山大学 吡唑并嘧啶酮衍生物及其可药用盐、其制备方法和应用

Similar Documents

Publication Publication Date Title
KR101626681B1 (ko) 피라졸로[3,4-d]피리미딘 화합물 및 pde2 억제제 및/또는 cyp3a4 억제제로서의 이의 용도
ES2794779T3 (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de JAK
TWI644671B (zh) P2x7調節劑
ES2541295T3 (es) Carboxamidas que modulan el receptor de andrógenos
ES2434467T3 (es) Compuestos multicíclicos y métodos para su uso
JP2023505258A5 (enExample)
JPWO2020122093A5 (enExample)
ES2807221T3 (es) Derivados de 4-azaindol
JP2012528166A5 (enExample)
RU2021133444A (ru) Производные бензимидазола в качестве модуляторов ror-гамма
JP2011500806A5 (enExample)
JP2018519323A5 (enExample)
JP2011523945A5 (enExample)
JP2016517878A5 (enExample)
JP2007519694A5 (enExample)
HRP20192323T1 (hr) Novi derivati dihidrokinolin-2-ona
RU2017125025A (ru) Конденсированные кольцевые гетероарильные соединения и их применение в качестве ингибиторов trk
CA2749040A1 (en) Triazolo and tetrazolo pyrimidine derivatives as hne inhibitors for treating copd
JP2007524696A5 (enExample)
JP2013523884A5 (enExample)
RU2014106020A (ru) Ингибиторы втк
KR20110059778A (ko) H-pgds 억제제로서 다중헤테로아릴 화합물 및 프로스타글란딘 d2 매개된 질병의 치료를 위한 그의 용도
JP2017530185A5 (enExample)
EP2933248B1 (en) Novel renin inhibitor
JP2021535134A5 (enExample)